Search

Is TRTH for me?

Please see the eligibility criteria in the dropdown menu below.

Read more

Presidential Speakers

Promising crucial developments in the field of hematology, the speakers and presentation topics of the EHA2025 Presidential Session speakers are now available. Friday, June 13, 2025 - Presidential Session I

Immunotherapy (TCR related)

Prof.

Read more

Spotlight on...

We talk to leaders, thinkers and influencers to hear their thoughts on #changeOfMindset #HotInHematology to provide a #VisionOfYourFuture.

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more